A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC)
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
Sponsor: Lantern Pharma Inc.
This PHASE2 trial investigates Adenocarcinoma of Lung and Carcinoma, Non-Small-Cell Lung and is currently actively recruiting participants. Lantern Pharma Inc. leads this study, which shows 18 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Aug 2025 [monthly]
Recruiting PHASE2
▶ Show 13 earlier versions
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Lantern Pharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .